MI Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E · adults with or without existing CVD
Higher showed no clear difference in MI Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E compared with lower omega‐6: additional key outcomes (low certainty).
1 finding from 1 review
Serum TC Study duration range 12‐96 months Omega‐6 dose range 2.0%‐24.5% E · adults with or without existing CVD
1 finding from 1 review
Serum TG Study duration range 12‐72 months Omega‐6 dose range 2.0%‐15.0% E · adults with or without existing CVD
1 finding from 1 review
All allergic disease ‐ Infancy (incidence) · infants
It is very uncertain whether higher changes all allergic disease ‐ infant incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
All allergic disease ‐ childhood prevalence · infants
It is very uncertain whether higher changes all allergic disease ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Asthma ‐ childhood prevalence · infants
It is very uncertain whether higher changes asthma ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Dermatitis/eczema ‐ childhood prevalence · infants
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Allergic rhinitis ‐ childhood prevalence · infants
It is very uncertain whether higher changes allergic rhinitis ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Food allergy ‐ childhood prevalence · infants
It is very uncertain whether higher changes food allergy ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Asthma ‐ Infancy (incidence) · infants
Higher showed no clear difference in asthma ‐ infant incidence compared with lower PUFA intake (low certainty).
1 finding from 1 review
Eczema ‐ Infancy (incidence) · infants
It is very uncertain whether higher changes dermatitis/eczema ‐ infant incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Allergic rhinitis ‐ infant incidence · infants
It is very uncertain whether higher changes allergic rhinitis ‐ infant incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Food allergy ‐ Infancy (incidence) · infants
It is very uncertain whether higher changes food allergy ‐ infant incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
All allergic disease ‐ childhood (incidence) · infants
It is very uncertain whether higher changes all allergic disease ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Asthma ‐ childhood (incidence) · infants
It is very uncertain whether higher changes asthma ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Eczema ‐ childhood (incidence) · infants
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Food allergy ‐ childhood (incidence) · infants
It is very uncertain whether higher changes food allergy ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
HDL‐cholesterol · Participants with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Risk of high altitude pulmonary oedema · participants at risk of high altitude illness
1 finding from 1 review
Risk of high altitude cerebral oedema · participants at risk of high altitude illness
1 finding from 1 review